Coronavirus: NAFDAC Approves Chloroquine For Clinical Trial Treatment

The Director General of NAFDAC National Agency for Food and Drug Administration and Control, Prof Mojisola Adeyeye, on Monday, ordered manufacturing of chloroquine  for possible clinical trial treatment of coronavirus.
Coronavirus: NAFDAC Orders Production Of Chloroquine
Coronavirus: NAFDAC Orders Production Of Chloroquine

“Chloroquine, an old anti-malarial, is being re-purposed for the clinical trial treatment of coronavirus 2019-nCoV. The drug was first tested in vitro (in the lab) using standard assays to measure the effects on the cytotoxicity, virus yield and infection rates of 2019-nCoV.

“About four weeks ago, I approached a local manufacturing company (May and Baker), a member of Pharmaceutical Manufacturing Group of Manufacturing Association of Nigeria, whose flagship product in the past was chloroquine, to make a batch of the drug for emergency stock. The DG stated that once the drug is sent back to the Nigeria Lagos will begin the use  of the drug for clinical trial.

The DG however stated that the drug should not be abused or sold to anyone without clinical direction as the abuse of the drug can lead to blurred vision, headache and hitching.

Photo Credit: Getty

Leave a Reply